| Assessment Status | Awaiting response from Applicant |
| HTA ID | 25057 |
| Drug | Teprotumumab |
| Brand | Tepezza® |
| Indication | Teprotumumab (Tepezza®) is indicated in adults for the treatment of moderate to severe thyroid eye disease. |
| Assessment Process | |
| Rapid review commissioned | 16/09/2025 |
| Rapid review completed | 15/10/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of teprotumumab compared with the current standard of care. |
| Full HTA commissioned by the HSE | 29/10/2025 |
| Pre-submission consultation with Applicant | 11/12/2025 |
| Full submission received from Applicant | 18/08/2026 |
| Preliminary review sent to Applicant | 15/10/2026 |
The assessment was paused on 29th October 2026 at the request of the Applicant.